P. Sauerberg

发表

Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

F. Bymaster, A. Fink-Jensen, C. Mitch, 1998, Brain Research.

1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.

L Jeppesen, J S Ward, F. Bymaster, 1998, Journal of medicinal chemistry.

Structure–Activity Relationships for Negative Allosteric mGluR5 Modulators

Christina Mølck, Hans Bräuner-Osborne, Kasper Harpsøe, 2012, ChemMedChem.

Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.

J. Fleckner, I. Pettersson, H. Deussen, 2003, Journal of medicinal chemistry.

Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, Schizophrenia Research.

Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice.

B. Ahrén, E. M. Wulff, M. S. Winzell, 2010, European journal of pharmacology.

Design and synthesis of novel PPARα/γ/δ triple activators using a known PPARα/γ dual activator as structural template

K. Wassermann, J. Fleckner, I. Pettersson, 2003 .

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls

T. Kruse, K. Raun, P. Sauerberg, 2022, PloS one.

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

F. Bymaster, L. Farde, P. Suzdak, 1997 .

Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites.

T. Liljefors, J. Kastrup, M. Gajhede, 2007, Chemistry & biology.

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, Schizophrenia research.

Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.

K. Wassermann, J. Fleckner, P. Sauerberg, 2003, Journal of molecular endocrinology.

Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

P. J. Larsen, K. Wassermann, J. Fleckner, 2008, European journal of pharmacology.

Selective PPAR Agonists for the Treatment of Type 2 Diabetes

J. Fleckner, E. M. Wulff, J. Nehlin, 2006, Annals of the New York Academy of Sciences.

Muscarinic agonists as analgesics. Antinociceptive activity versus M1 activity: SAR of alkylthio-TZTP's and related 1,2,5-thiadiazole analogs.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1995, Life sciences.

Xanomeline: An Efficacious and Specific M1 Receptor Agonist — Preclinical Update

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1994 .

Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, Journal of medicinal chemistry.

Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.

F. Bymaster, A. Fink-Jensen, C. Mitch, 1998, Biochemical and biophysical research communications.

Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice.

B. Ahrén, C. Thomsen, P. Sauerberg, 1999, The American journal of physiology.

PPARδ agonists have opposing effects on insulin resistance in high fat‐fed rats and mice due to different metabolic responses in muscle

N. Turner, Xiao-Yi Zeng, G. Cooney, 2011, British journal of pharmacology.

Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.

M. Havranek, J. Fleckner, J. Daugaard, 2007, Journal of medicinal chemistry.

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

M1 receptor agonist activity is not a requirement for muscarinic antinociception.

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1997, The Journal of pharmacology and experimental therapeutics.

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .

J S Ward, F. Bymaster, A. Pike, 1992, Journal of medicinal chemistry.

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, The Journal of pharmacology and experimental therapeutics.

Potential role of muscarinic receptors in schizophrenia.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, Life sciences.

Process Development and Scale-Up of the PPAR Agonist NNC 61-4655

H. Deussen, L. Jeppesen, P. Sauerberg, 2004 .

E/Z Isomerization of 3,3-disubstituted allylic thioethers

M. Havranek, P. Kratina, P. Sauerberg, 2007 .

Design of a partial PPARδ agonist

M. Havranek, I. Pettersson, P. Sauerberg, 2007 .

Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.

M. Havranek, I. Pettersson, P. Kratina, 2007, Bioorganic & medicinal chemistry letters.

Structure-activity relationships of dimeric PPAR agonists.

Ingrid Pettersson, J. Fleckner, I. Pettersson, 2005, Bioorganic & medicinal chemistry letters.

Inverse isostere strategies in the development of cholinergic agonists with multiple therapeutic potentials

F. Bymaster, Michael D B Swedberg, C. Mitch, 1997 .

Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.

D. Wong, F. Bymaster, P. Suzdak, 1997, The Journal of pharmacology and experimental therapeutics.

1,2,5-Thiadiazole derivatives of arecoline stimulate M1 receptors coupled to phosphoinositide turnover

W. Hoss, S. Periyasamy, P. Sauerberg, 1995, Brain Research.

Central muscarinic inhibition of lower urinary tract nociception

K. Thor, H. Shannon, P. Sauerberg, 2000, Brain Research.

3-(3-Alkylthio- 1,2,5-thiadiazol-4-yl)- 1 -azabicycles. Structure-activity relationships for antinociception mediated by central muscarinic receptors

F. Bymaster, P. Suzdak, Michael D B Swedberg, 1996 .

Pharmacological profile of a novel class of muscarinic acetylcholine receptor agonists.

P. Krogsgaard‐Larsen, E. Falch, J. Larsen, 1986, European journal of pharmacology.

Analgesic Effects of Vedaclidine, a Mixed Agonist ‚Äì Antagonist at Muscarinic Receptor Subtypes

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2003 .

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1997, Life sciences.

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1998, European journal of pharmacology.

Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.

F. Bymaster, A. Fink-Jensen, J. Ward, 1998, Bioorganic & Medicinal Chemistry Letters.

Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists.

A. Christopoulos, L. Jeppesen, P. Sauerberg, 2001, The Journal of pharmacology and experimental therapeutics.

Identification of Side Chains on 1,2,5‐Thiadiazole‐azacycles Optimal for Muscarinic M1 Receptor Activation.

P. Sauerberg, A. L. A. L. E. Et, 1999 .

Synthesis and structural determination of stereoisomers of muscarinic ligands of the (3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicycloalkane type.

C. Mitch, J. Deeter, J. Ward, 1997, Chirality.

A novel class of conformationally restricted heterocyclic muscarinic agonists.

E Falch, P. Krogsgaard‐Larsen, E. Falch, 1986, Journal of medicinal chemistry.

Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

D. Wong, F. Bymaster, P. Suzdak, 1994, The Journal of pharmacology and experimental therapeutics.

SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIPS OF ALKYL SUBSTITUTED ANALOGUES OF THE FUNCTIONAL M1 SELECTIVE MUSCARINIC RECEPTOR AGONIST XANOMELINE

F. Bymaster, P. Suzdak, C. Mitch, 1994 .

Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity

Ingrid Pettersson, Jeppe Sturis, J. Sturis, 2002 .

Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships.

T. Honoré, P Sauerberg, M. Sheardown, 1991, Journal of medicinal chemistry.

Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats

J. Sturis, K. Wassermann, B. Hansen, 2003 .

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.

J. Sturis, K. Wassermann, B. Hansen, 2003, American journal of physiology. Endocrinology and metabolism.

Novel Functional M1 Selective Muscarinic Agonists. Synthesis and Structure→Activity Relationships of 3‐(1,2,5‐Thiadiazolyl)‐1,2,5,6‐tetrahydro‐1‐methylpyridines.

F. Bymaster, A. Pike, C. Mitch, 1992 .

Steric and electronic requirements for muscarinic receptor-stimulated phosphoinositide turnover in the CNS in a series of arecoline bioisosteres.

W. Hoss, C. Mitch, S. Quimby, 1992, Biochemical and biophysical research communications.

Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres.

E Falch, E Meier, P. Krogsgaard‐Larsen, 1988, Journal of medicinal chemistry.

Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, European journal of pharmacology.

Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.

J. Sturis, K. Wassermann, J. Fleckner, 2002, Journal of medicinal chemistry.

Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles Published, JLR Papers in Press, December 16, 2003. DOI 10.1194/jlr.M300239-JLR200

J. Fleckner, E. M. Wulff, L. Jeppesen, 2004, Journal of Lipid Research.

Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles.

J. Fleckner, E. M. Wulff, L. Jeppesen, 2004, Journal of lipid research.

Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice.

B. Ahrén, C. Thomsen, P. Sauerberg, 1999, American journal of physiology. Endocrinology and metabolism.

Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats.

F. Bymaster, A. Fink-Jensen, P. Kristensen, 1998, Neuroreport.

PPARδ agonists have opposing effects on insulin resistance in high fat‐fed rats and mice due to different metabolic responses in muscle

N. Turner, Xiao-Yi Zeng, G. Cooney, 2011, British journal of pharmacology.

tolerance by cholinergic agonism in high fat-fed mice Increased insulin secretion and normalization of glucose

B. Ahrén, C. Thomsen, P. Sauerberg, 2016 .

Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.

J S Ward, F. Bymaster, Michael D B Swedberg, 1995, Journal of medicinal chemistry.